Last reviewed · How we verify

NCT06074133

A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules

Recruiting now Last updated 13 March 2026
What this trial tests

trial testing Blood collection in Pulmonary Nodule in 100 participants. Currently enrolling.

Timeline
7 March 2024
Primary endpoint
31 March 2027
31 March 2029

Quick facts

Lead sponsorVanderbilt-Ingram Cancer Center
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment100
Start date7 March 2024
Primary completion31 March 2027
Estimated completion31 March 2029
Sites4 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Vanderbilt-Ingram Cancer Center — full company profile →

Who can join

21 and older, any sex, with Pulmonary Nodule. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective, multicenter observational study aim at estimating the potential clinical utility of the CBM and at establishing the SOPs and protocols for a future randomized control trial.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Blood collection

Trials testing the same drug.

Other recruiting trials for Pulmonary Nodule

Currently open trials in the same condition.

Other Vanderbilt-Ingram Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06074133.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing